跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00541073
NCT00541073已完成2 期

Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma

Centre Oscar Lambret2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2007年6月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
2
主要终点
Individual dosage-adapted protocol
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

RATIONALE: Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving pemetrexed together with cisplatin and vitamin B12 may kill more tumor cells.

PURPOSE: This phase II clinical trial is studying how well giving pemetrexed together with cisplatin and vitamin B12 works in treating patients with mesothelioma of the chest that cannot be removed by surgery.

详细描述

OBJECTIVES:

Primary

  • Define an individually adapted (by dosage) protocol of pemetrexed disodium, cisplatin, and vitamin B12 in patients with unresectable pleural mesothelioma.

Secondary

  • Determine the relationship between pharmacokinetic and pharmacodynamic parameters (hematologic and nonhematologic).
  • Analyze the inter-individual pharmacokinetic variations and the influence of the covariables on the pharmacokinetics of pemetrexed disodium.
  • Analyze the impact of pharmacogenetic (MTHFR, TS, GSTpi, ERCC1, XPD) variations on the toxicity of pemetrexed disodium.
  • Validate a strategy of adapting dosage.

研究设计

研究类型
Interventional
分配方式
Non Randomized
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Individual dosage-adapted protocol

次要结局

  • Relationship between pharmacokinetic and pharmacodynamic parameters
  • Pharmacokinetics
  • Pharmacogenetic variations (MTHFR, TS, GSTpi, ERCC1, XPD)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

已完成
2 期
Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck CancerHead and Neck Cancer
NCT00503997Vanderbilt-Ingram Cancer Center42
已完成
2 期
Pemetrexed and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical CancerCervical Cancer
NCT00691301Gynecologic Oncology Group55
终止
1 期
Pemetrexed, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic CancerPancreatic Cancer
NCT00310050Wake Forest University Health Sciences4
终止
2 期
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerLung Cancer
NCT00438204Barbara Ann Karmanos Cancer Institute39
已完成
2 期
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line ChemotherapyMalignant Mesothelioma
NCT01085630Alliance for Clinical Trials in Oncology72